The eye is a well-suited organ for local delivery of therapeutics to treat vitreous inflammation as well as other pathologic conditions that induce visual loss. Several conditions are particularly challenging to treat and often require chronic courses of therapy. The use of implantable intravitreal devices for drug delivery is an emerging field in the treatment of vitreous inflammation as well as other ophthalmologic diseases. There are unique challenges in the design of these devices which include implants, polymers, and micro- and nanoparticles. This paper reviews current and investigational drug delivery systems for treating vitreous inflammation as well as other pathologic conditions that induce visual loss. The use of nonbiodegradable devices such as polyvinyl alcohol-ethylene vinyl acetate polymers and polysulfone capillary fibers, and biodegradable devices such as polylactic acid, polyglycolic acid, and polylactic-co-glycolic acid, polycaprolactones, and polyanhydrides are reviewed. Clinically used implantable devices for therapeutic agents including ganciclovir, fluocinolone acetonide, triamcinolone acetonide, and dexamethasone are described. Finally, recently developed investigational particulate drug delivery systems in the form of liposomes, microspheres, and nanoparticles are examined. 1. Introduction The eye is a model organ for the implantation of devices that provide long-lasting infusion of a therapeutic agent. It is easily accessible for implantation of such a device and success of therapy is measurable objectively by direct visualization of the intraocular structures and by patient responsiveness. The treatment of posterior uveitis and vitreous inflammation usually involves a chronic course of therapy often over a period of years. Topical agents require frequent administration which is often impractical for patients. Sub-Tenon’s and intravitreal steroid injections also can require frequent retreatment to adequately control disease. Treatment with powerful systemic corticosteroid and immunomodulatory agents most often have poor vitreous penetration and can be associated with severe systemic side effects [1]. Implantable devices offer an alternative therapeutic approach that can circumvent many challenges of these other modes of therapy. The first implantable device for clinical use was developed in 1992 [2]. Vitrasert, a nonbiodegradable implant, delivers ganciclovir into the eye for the treatment of acquired-immunodeficiency-syndrome (AIDS)-related cytomegalovirus (CMV). Newer biodegradable implantable devices can provide sustained
References
[1]
S. Duvvuri, S. Majumdar, and A. K. Mitra, “Drug delivery to the retina: challenges and opportunities,” Expert Opinion on Biological Therapy, vol. 3, no. 1, pp. 45–56, 2003.
[2]
T. J. Smith, P. A. Pearson, D. L. Blandford et al., “Intravitreal sustained-release ganciclovir,” Archives of Ophthalmology, vol. 110, no. 2, pp. 255–258, 1992.
[3]
S. S. Lee, P. Hughes, A. D. Ross, and M. R. Robinson, “Biodegradable implants for sustained drug release in the eye,” Pharmaceutical Research, vol. 27, no. 10, pp. 2043–2053, 2010.
[4]
J. I. Lim, R. A. Wolitz, A. H. Dowling, H. R. Bloom, A. R. Irvine, and D. M. Schwartz, “Visual and anatomic outcomes associated with posterior segment complications after ganciclovir implant procedures in patients with AIDS and cytomegalovirus retinitis,” American Journal of Ophthalmology, vol. 127, no. 3, pp. 288–293, 1999.
[5]
D. L. Blandford, T. J. Smith, J. D. Brown, P. A. Pearson, and P. Ashton, “Subconjunctival sustained release 5-fluorouracil,” Investigative Ophthalmology and Visual Science, vol. 33, no. 12, pp. 3430–3435, 1992.
[6]
C. K. Cheng, A. S. Berger, P. A. Pearson, P. Ashton, and G. J. Jaffe, “Intravitreal sustained-release dexamethasone device in the treatment of experimental uveitis,” Investigative Ophthalmology and Visual Science, vol. 36, no. 2, pp. 442–453, 1995.
[7]
P. A. Pearson, G. J. Jaffe, D. F. Martin et al., “Evaluation of a delivery system providing long-term release of cyclosporine,” Archives of Ophthalmology, vol. 114, no. 3, pp. 311–317, 1996.
[8]
M. H. Rahimy, G. A. Peyman, S. Y. Chin et al., “Polysulfone capillary fiber for intraocular drug delivery: in vitro and in vivo evaluations,” Journal of Drug Targeting, vol. 2, no. 4, pp. 289–298, 1994.
[9]
M. H. Rahimy, G. A. Peyman, M. L. Fernandes, S. H. El-Sayed, Q. Luo, and H. Borhani, “Effects of an intravitreal daunomycin implant on experimental proliferative vitreoretinopathy: simultaneous pharmacokinetic and pharmacodynamic evaluations,” Journal of Ocular Pharmacology, vol. 10, no. 3, pp. 561–570, 1994.
[10]
R. Jain, N. H. Shah, A. W. Malick, and C. T. Rhodes, “Controlled drug delivery by biodegradable poly(ester) devices: different preparative approaches,” Drug Development and Industrial Pharmacy, vol. 24, no. 8, pp. 703–727, 1998.
[11]
E. Bowland, G. Wnek, and G. Bowlin, “Poly(glycolic acid),” in Encyclopedia of Biomaterials and Biomedical Engineering, G. E. Wnek and G. L. Bowlin, Eds., pp. 2241–2248, Marcel Dekker, New York, NY, USA, 2008.
[12]
M. S. Shive and J. M. Anderson, “Biodegradation and biocompatibility of PLA and PLGA microspheres,” Advanced Drug Delivery Reviews, vol. 28, no. 1, pp. 5–24, 1997.
[13]
T. Yasukawa, H. Kimura, N. Kunou et al., “Biodegradable scleral implant for intravitreal controlled release of ganciclovir,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 238, no. 2, pp. 186–190, 2000.
[14]
N. Kunou, Y. Ogura, T. Yasukawa et al., “Long-term sustained release of ganciclovir from biodegradable scleral implant for the treatment of cytomegalovirus retinitis,” Journal of Controlled Release, vol. 68, no. 2, pp. 263–271, 2000.
[15]
C. Pitt, “Poly-e-caprolactone and its copolymers,” in Biodegradable Polymers as Drug Delivery Systems, M. Chasin and R. S. Langer, Eds., p. 71, Marcel Dekker, New York, NY, USA, 1990.
[16]
G. A. Peyman, B. Khoobehi, S. Shaibani, S. Shamsnia, and I. Ribeiro, “A fluorescent vesicle system for the measurement of blood velocity in the choroidal vessels,” Ophthalmic Surgery and Lasers, vol. 27, no. 6, pp. 459–466, 1996.
[17]
J. S. Chawla and M. M. Amiji, “Biodegradable poly(ε-caprolactone) nanoparticles for tumor-targeted delivery of tamoxifen,” International Journal of Pharmaceutics, vol. 249, no. 1-2, pp. 127–138, 2002.
[18]
H. Borhani, G. A. Peyman, M. H. Rahimy, and H. Thompson, “Suppression of experimental proliferative vitreoretinopathy by sustained intraocular delivery of 5-FU,” International Ophthalmology, vol. 19, no. 1, pp. 43–49, 1995.
[19]
A. Silva-Cunha, S. L. Fialho, M. C. Naud, and F. Behar-Cohen, “Poly-epsilon-caprolactone intravitreous devices: an in vivo study,” Investigative Ophthalmology and Visual Science, vol. 50, no. 5, pp. 2312–2318, 2009.
[20]
N. R. F. Beeley, J. V. Rossi, P. A. A. Mello-Filho et al., “Fabrication, implantation, elution, and retrieval of a steroid-loaded polycaprolactone subretinal implant,” Journal of Biomedical Materials Research Part A, vol. 73, no. 4, pp. 437–444, 2005.
[21]
X. Dong, W. Shi, G. Yuan, L. Xie, S. Wang, and P. Lin, “Intravitreal implantation of the biodegradable cyclosporin A drug delivery system for experimental chronic uveitis,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 244, no. 4, pp. 492–497, 2006.
[22]
W. Shi, T. Liu, L. Xie, and S. Wang, “FK506 in a biodegradable glycolide-co-clatide-co-caprolactone polymer for prolongation of corneal allograft survival,” Current Eye Research, vol. 30, no. 11, pp. 969–976, 2005.
[23]
K. E. Uhrich, S. M. Cannizzaro, R. S. Langer, and K. M. Shakesheff, “Polymeric systems for controlled drug release,” Chemical Reviews, vol. 99, no. 11, pp. 3181–3198, 1999.
[24]
J. P. Jain, S. Modi, A. J. Domb, and N. Kumar, “Role of polyanhydrides as localized drug carriers,” Journal of Controlled Release, vol. 103, no. 3, pp. 541–563, 2005.
[25]
K. W. Leong, V. Simonte, and R. Langer, “Synthesis of polyanhydrides: melt-polycondensation, dehydrochlorination, and dehydrative coupling,” Macromolecules, vol. 20, no. 4, pp. 705–712, 1987.
[26]
H. D. Jampel, K. W. Leong, G. R. Dunkelburger, and H. A. Quigley, “Glaucoma filtration surgery in monkeys using 5-fluorouridine in polyanhydride disks,” Archives of Ophthalmology, vol. 108, no. 3, pp. 430–435, 1990.
[27]
H. D. Jampel, P. Koya, K. Leong, and H. A. Quigley, “In vitro release of hydrophobic drugs from polyanhydride disks,” Ophthalmic Surgery, vol. 22, no. 11, pp. 676–680, 1991.
[28]
D. F. Martin, D. J. Parks, S. D. Mellow et al., “Treatment of cytomegalovirus retinitis with an intraocular sustained- release ganciclovir implant: a randomized controlled clinical trial,” Archives of Ophthalmology, vol. 112, no. 12, pp. 1531–1539, 1994.
[29]
G. J. Jaffe, J. Ben-nun, H. Guo, J. P. Dunn, and P. Ashton, “Fluocinolone acetonide sustained drug delivery devine to treat severe uveitis,” Ophthalmology, vol. 107, no. 11, pp. 2024–2033, 2000.
[30]
G. J. Jaffe, D. Martin, D. Callanan, P. A. Pearson, B. Levy, and T. Comstock, “Fluocinolone acetonide implant (retisert) for noninfectious posterior uveitis. Thirty-four-week results of a multicenter randomized clinical study,” Ophthalmology, vol. 113, no. 6, pp. 1020–1027, 2006.
[31]
D. G. Callanan, G. J. Jaffe, D. F. Martin, P. A. Pearson, and T. L. Comstock, “Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results,” Archives of Ophthalmology, vol. 126, no. 9, pp. 1191–1201, 2008.
[32]
D. A. Goldstein, D. G. Godfrey, A. Hall et al., “Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants,” Archives of Ophthalmology, vol. 125, no. 11, pp. 1478–1485, 2007.
[33]
J. H. Kempen, M. M. Altaweel, J. T. Holbrook, et al., “Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial,” Ophthalmology, vol. 118, no. 10, pp. 1916–1926, 2011.
[34]
P. A. Campochiaro, D. M. Brown, A. Pearson, et al., “Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema,” Ophthalmology. In press.
[35]
“SurModics I-vationTM Sustained Drug Delivery System: Intravitreal Implant for Drug Delivery,” 2010, http://www.surmodics.com/pdf/ophthalmology.pdf.
[36]
P. U. Dugel, D. Eliott, H. L. Cantrill, et al., “I-Vation TA: 24-month clinical results of the Phase I safety and preliminary efficacy study,” in Proceedings of ARVO Annual Meeting, Fort Lauderdale, Fla, USA, 2009.
[37]
M. Hu, G. Huang, F. Karasina, and V. G. Wong, “Verisome, a novel injectable, sustained release, biodegradable, intraocular drug delivery system and triamcinolone acetonide,” Investigative Ophthalmology and Visual Science, vol. 49, E-Abstract 5627, 2008.
[38]
J. L. Edelman, “Differentiating intraocular glucocorticoids,” Ophthalmologica, vol. 224, no. 1, supplement, pp. 25–30, 2010.
[39]
C. Lowder, R. Belfort, S. Lightman et al., “Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis,” Archives of Ophthalmology, vol. 129, no. 5, pp. 545–553, 2011.
[40]
R. S. Hunter and A. M. Lobo, “Dexamethasone intravitreal implant for the treatment of noninfectious uveitis,” Clinical Ophthalmology, vol. 5, pp. 1613–1621, 2011.
[41]
D. T. H. Tan, S. P. Chee, L. Lim, and A. S. M. Lim, “Randomized clinical trial of a new dexamethasone delivery system (Surodex) for treatment of post-cataract surgery inflammation,” Ophthalmology, vol. 106, no. 2, pp. 223–231, 1999.
[42]
B. C. Gilger, J. H. Salmon, D. A. Wilkie et al., “A novel bioerodible deep scleral lamellar cyclosporine implant for uveitis,” Investigative Ophthalmology and Visual Science, vol. 47, no. 6, pp. 2596–2605, 2006.
[43]
O. Nishi, K. Nishi, T. Morita, Y. Tada, E. Shirasawa, and K. Sakanishi, “Effect of intraocular sustained release of indomethacin on postoperative inflammation and posterior capsule opacification,” Journal of Cataract and Refractive Surgery, vol. 22, supplement, pp. 806–810, 1996.
[44]
D. Ghate and H. F. Edelhauser, “Ocular drug delivery,” Expert Opinion on Drug Delivery, vol. 3, no. 2, pp. 275–287, 2006.
[45]
M. Barza, J. Baum, and C. Tremblay, “Ocular toxicity of intravitreally injected liposomal amphotericin B in rhesus monkeys,” American Journal of Ophthalmology, vol. 100, no. 2, pp. 259–263, 1985.
[46]
J. Kreuter, “Nanoparticles,” in Encyclopedia of Pharmaceutical Technology, J. Swarbrick and J. C. Boylan, Eds., pp. 165–190, Marcel Dekker, New York, NY, USA, 1994.
[47]
C. Roney, P. Kulkarni, V. Arora et al., “Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease,” Journal of Controlled Release, vol. 108, no. 2-3, pp. 193–214, 2005.
[48]
L. R. Beck, D. R. Cowsar, and D. H. Lewis, “A new long-acting injectable microcapsule system for the administration of progesterone,” Fertility and Sterility, vol. 31, no. 5, pp. 545–551, 1979.
[49]
T. Moritera, Y. Ogura, N. Yoshimura et al., “Biodegradable microspheres containing adriamycin in the treatment of proliferative vitreoretinopathy,” Investigative Ophthalmology and Visual Science, vol. 33, no. 11, pp. 3125–3130, 1992.
[50]
K. G. Carrasquillo, J. A. Ricker, I. K. Rigas, J. W. Miller, E. S. Gragoudas, and A. P. Adamis, “Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres,” Investigative Ophthalmology and Visual Science, vol. 44, no. 1, pp. 290–299, 2003.
[51]
I. Genta, B. Conti, P. Perugini, F. Pavanetto, A. Spadaro, and G. Puglisi, “Bioadhesive microspheres for ophthalmic administration of acyclovir,” Journal of Pharmacy and Pharmacology, vol. 49, no. 8, pp. 737–742, 1997.
[52]
Y. He, Y. Liu, Y. Liu et al., “Cyclosporine-loaded microspheres for treatment of uveitis: in vitro characterization and in vivo pharmacokinetic study,” Investigative Ophthalmology and Visual Science, vol. 47, no. 9, pp. 3983–3988, 2006.
[53]
Y. de Kozak, K. Andrieux, H. Villarroya et al., “Intraocular injection of tamoxifen-loaded nanoparticles: a new treatment of experimental autoimmune uveoretinitis,” European Journal of Immunology, vol. 34, no. 12, pp. 3702–3712, 2004.
[54]
M. S. El-Samaligy, Y. Rojanasakul, J. F. Charlton, G. W. Weinstein, and J. K. Lim, “Ocular disposition of nanoencapsulated acyclovir and ganciclovir via intravitreal injection in rabbit's eye,” Drug Delivery, vol. 3, no. 2, pp. 93–97, 1996.
[55]
P. Gehlbach, A. M. Demetriades, S. Yamamoto et al., “Periocular injection of an adenoviral vector encoding pigment epithelium-derived factor inhibits choroidal neovascularization,” Gene Therapy, vol. 10, no. 8, pp. 637–646, 2003.
[56]
Y. Saishin, R. L. Silva, Y. Saishin et al., “Periocular gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization in a human-sized eye,” Human Gene Therapy, vol. 16, no. 4, pp. 473–478, 2005.
[57]
P. A. Campochiaro, Q. D. Nguyen, S. M. Shah et al., “Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial,” Human Gene Therapy, vol. 17, no. 2, pp. 167–176, 2006.